TCT 2017: PREVAIL's Watchman is effective, but not '1st-line therapy' for AFib
Cardiovascular Business,
A meta-analysis of the PREVAIL and PROTECT trials, two studies aimed at evaluating the efficacy of left atrial appendage…
A meta-analysis of the PREVAIL and PROTECT trials, two studies aimed at evaluating the efficacy of left atrial appendage…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Boston Scientific Corporation Late-breaking Clinical Trial Data Presented at TCT 2017 with Simultaneous Publication in…
SOURCE Boston Scientific Corporation Late-breaking Clinical Trial Data Presented at TCT 2017 with Simultaneous Publication in…